IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This project is a retrospective (beginning January 2006) and prospective patient registry program sponsored by Ipsen (formerly Tercica, Inc.). In collaboration with participating health care practitioners, the patient registry program is an observational study monitoring the long-term safety of patients treated with Increlex® (mecasermin [rDNA origin] injection). The IGFD (Increlex® Growth Forum Database) Registry is intended primarily to monitor the safety and efficacy of Increlex replacement therapy in children with growth failure.
| Condition | Intervention |
|---|---|
|
Primary Insulin-like Growth Factor-1 Deficiency |
Biological: mecasermin [rDNA origin] injection |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only |
| Official Title: | Increlex® (Mecasermin [rDNA Origin] Injection) Growth Forum Database - IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex |
- To obtain long-term safety and efficacy data for Increlex® replacement therapy in children with growth failure [ Time Frame: periodically assessed over the course of the study ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 250 |
| Study Start Date: | May 2006 |
| Estimated Study Completion Date: | December 2020 |
| Estimated Primary Completion Date: | June 2020 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Increlex patients
Eligible patients will be patients beginning therapy with Increlex® or those previously treated with Increlex.
|
Biological: mecasermin [rDNA origin] injection
As prescribed by the physician.
Other Name: Increlex®
|
Detailed Description:
The data collected for a patient will be those that exist in the patient's medical record as part of standard medical care. No additional patient procedures or activities are mandated by this study. The specific data to be collected at each visit and the schedule of data collection are listed in a schedule of assessments.
The collection of safety events is considered essential to the Registry. The website will provide the opportunity to report the occurrence of targeted adverse events (AEs), other important events considered to be related to Increlex administration and serious adverse events (SAEs).
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Eligible patients will be patients beginning therapy with Increlex® or those previously treated with Increlex.
Inclusion Criteria:
- Parents or legally authorized representatives must give signed informed consent before any Registry-related activities are conducted. Assent from the subject should also be obtained where appropriate.
- Patients receiving Increlex® by a qualified practitioner may be enrolled
Exclusion Criteria:
Contacts and Locations| Contact: Ipsen Central Contact | clinical.trials@ipsen.com |
| United States, New Jersey | |
| Ipsen Central Contact | Recruiting |
| Basking Ridge, New Jersey, United States, 07920 | |
| Study Director: | Kathleen Lomax, M.D. | Ipsen (formerly Tercica) |
More Information
Additional Information:
No publications provided
| Responsible Party: | Ipsen |
| ClinicalTrials.gov Identifier: | NCT00747604 History of Changes |
| Other Study ID Numbers: | W-TG-52800-010 (MS305) |
| Study First Received: | September 3, 2008 |
| Last Updated: | April 23, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Ipsen:
|
Growth Hormone (GH) Insensitivity Syndrome Insulin-like Growth Factor Deficiency (IGFD) Short Stature Insulin-like Growth Factor (IGF-1) Growth |
ClinicalTrials.gov processed this record on May 21, 2013